Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 491

Results For "CE"

8994 News Found

Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
News | May 12, 2025

Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr

The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025


Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr
News | May 12, 2025

Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr

The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025


Granules India bags EcoVadis’ Gold Rating
Sustainability | May 08, 2025

Granules India bags EcoVadis’ Gold Rating

The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence


Europe (AGES, Austria) inspects Shilpa Biologicals’ Dharwad site
Drug Approval | May 06, 2025

Europe (AGES, Austria) inspects Shilpa Biologicals’ Dharwad site

he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice


Briefs: Tatva Chintan Pharma Chem and Shelter Pharma
News | May 06, 2025

Briefs: Tatva Chintan Pharma Chem and Shelter Pharma

Tatva Chintan Pharma Chem receives export order worth $35, 55,000


Roquette completes acquisition of IFF Pharma Solutions
News | May 05, 2025

Roquette completes acquisition of IFF Pharma Solutions

The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide


Ami Organics Q4 FY25 PAT up at Rs. 62.48 Cr
News | May 05, 2025

Ami Organics Q4 FY25 PAT up at Rs. 62.48 Cr

The company has posted net profit of Rs. 158.71 crores for the Financial Year ended March 31, 2025


Tatva Chintan Pharma Chem reports consolidated Q4 FY25 PAT at Rs. 1.03 Cr
News | May 05, 2025

Tatva Chintan Pharma Chem reports consolidated Q4 FY25 PAT at Rs. 1.03 Cr

The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025


Biocon Biologics secures strong market coverage for Yesintek in US
News | May 05, 2025

Biocon Biologics secures strong market coverage for Yesintek in US

Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025